Search

Your search keyword '"Giske, C.G."' showing total 31 results
Start Over Author "Giske, C.G."
31 results on '"Giske, C.G."'

3. ESCMID generic competencies in antimicrobial prescribing and stewardship: towards a European consensus

Author

Ashiru-Oredope, D., Barcs, I., Blix, H.S., Buyle, F., Chowers, M., Čižman, M., Cookson, B., Del Pozo, J.L., Deptula, A., Dumpis, U., Florea, D., van de Garde, E., Geffen, Y., Giske, C.G., Grau, S., Hajdú, E., Hell, M., Hondo, Ł., Hussein, K., Huttner, B., Kern, W., Kernéis, S., Knepper, V., Kofteridis, D., Kostyanev, T., Kuijper, E., Lebanova, H., Lewis, R., Cordina, C.M., Matulionyte, R., Maurer, F., Messiaen, P., Miciuleviciene, J., Mrhar, A., Nabuurs-Franssen, M., Naesens, R., Oxacelay, C., Pagani, L., Paño-Pardo, J.R., Paul, M., Petrikkos, G., Pluess-Suard, C., Popescu, G.A., Porsche, U., Prins, J., Pulcini, C., Rello, J., Rodríguez-Baño, J., Rossolini, G.M., Salzberger, B., Seme, K., Simonsen, G.S., Sînziana, M., Skovgaard, S., Smith, I., Sönsken, U., Soriano, A., Sviestiņa, I., Szilagyi, E., Tängdén, T., Tattevin, P., Tsioutis, C., Vilde, A., Wanke-Rytt, M., Wechsler-Fördös, A., Zarb, P., Dyar, O.J., Beović, B., Tacconelli, E., and Hulscher, M.

Published
2019
Full Text
View/download PDF

8. Duration of Treatment for Pseudomonas aeruginosa Bacteremia: a Retrospective Study

Author

Babich, T., Naucler, P., Valik, J.K., Giske, C.G., Benito, Natividad, Cardona, R., Rivera, Alba, Pulcini, C., Fattah, M.A., Haquin, J., Macgowan, A., Grier, S., Chazan, B., Yanovskay, A., Ami, R.B., Landes, M., Nesher, L., Zaidman-Shimshovitz, A., McCarthy, K., Paterson, D.L., Tacconelli, E., Buhl, M., Mauer, S., Rodríguez-Baño, J., de Cueto, M., Oliver, A., de Gopegui, E.R., Cano, A., Machuca, I., Gozalo-Marguello, M., Martinez-Martinez, L., Gonzalez-Barbera, E.M., Alfaro, I.G., Salavert, M., Beovic, B., Saje, A., Mueller-Premru, M., Pagani, L., Vitrat, V., Kofteridis, D., Zacharioudaki, M., Maraki, S., Weissman, Y., Paul, M., Dickstein, Y., Leibovici, L., Yahav, D., Universitat Autònoma de Barcelona, and Yahav, Dafna

Subjects
Microbiology (medical), Infectious Diseases, Duration, Antibiotics, Pseudomonas aeruginosa, Bacteremia, Antimicrobial stewardship
Abstract

[Introduction] There is no consensus regarding optimal duration of antibiotic therapy for Pseudomonas aeruginosa bacteremia. We aimed to evaluate the impact of short antibiotic course., [Methods] We present a retrospective multicenter study including patients with P. aeruginosa bacteremia during 2009–2015. We evaluated outcomes of patients treated with short (6–10 days) versus long (11–15 days) antibiotic courses. The primary outcome was a composite of 30-day mortality or bacteremia recurrence and/or persistence. Univariate and inverse probability treatment-weighted (IPTW) adjusted multivariate analysis for the primary outcome was performed. To avoid immortal time bias, the landmark method was used., [Results] We included 657 patients; 273 received a short antibiotic course and 384 a long course. There was no significant difference in baseline characteristics of patients. The composite primary outcome occurred in 61/384 patients in the long-treatment group (16%) versus 32/273 in the short-treatment group (12%) (p = 0.131). Mortality accounted for 41/384 (11%) versus 25/273 (9%) of cases, respectively. Length of hospital stay was significantly shorter in the short group [median 13 days, interquartile range (IQR) 9–21 days, versus median 15 days, IQR 11–26 days, p = 0.002]. Ten patients in the long group discontinued antibiotic therapy owing to adverse events, compared with none in the short group. On univariate and multivariate analyses, duration of therapy was not associated with the primary outcome., [Conclusions] In this retrospective study, 6–10 days of antibiotic course for P. aeruginosa bacteremia were as effective as longer courses in terms of survival and recurrence. Shorter therapy was associated with reduced length of stay and less drug discontinuation.

Published
2022

20. Isothermal microcalorimetry minimal inhibitory concentration testing in extensively drug resistant Gram-negative bacilli: a multicentre study

Author

Tellapragada, C., primary, Hasan, B., additional, Antonelli, A., additional, Maruri, A., additional, de Vogel, C., additional, Gijón, D., additional, Coppi, M., additional, Verbon, A., additional, van Wamel, W., additional, Rossolini, G.M., additional, Cantón, R., additional, and Giske, C.G., additional

Published
2020
Full Text
View/download PDF

23. ESCMID generic competencies in antimicrobial prescribing and stewardship: towards a European consensus

Author

Dyar, O.J., primary, Beović, B., additional, Pulcini, C., additional, Tacconelli, E., additional, Hulscher, M., additional, Cookson, B., additional, Ashiru-Oredope, D., additional, Barcs, I., additional, Blix, H.S., additional, Buyle, F., additional, Chowers, M., additional, Čižman, M., additional, Del Pozo, J.L., additional, Deptula, A., additional, Dumpis, U., additional, Florea, D., additional, van de Garde, E., additional, Geffen, Y., additional, Giske, C.G., additional, Grau, S., additional, Hajdú, E., additional, Hell, M., additional, Hondo, Ł., additional, Hussein, K., additional, Huttner, B., additional, Kern, W., additional, Kernéis, S., additional, Knepper, V., additional, Kofteridis, D., additional, Kostyanev, T., additional, Kuijper, E., additional, Lebanova, H., additional, Lewis, R., additional, Cordina, C.M., additional, Matulionyte, R., additional, Maurer, F., additional, Messiaen, P., additional, Miciuleviciene, J., additional, Mrhar, A., additional, Nabuurs-Franssen, M., additional, Naesens, R., additional, Oxacelay, C., additional, Pagani, L., additional, Paño-Pardo, J.R., additional, Paul, M., additional, Petrikkos, G., additional, Pluess-Suard, C., additional, Popescu, G.A., additional, Porsche, U., additional, Prins, J., additional, Rello, J., additional, Rodríguez-Baño, J., additional, Rossolini, G.M., additional, Salzberger, B., additional, Seme, K., additional, Simonsen, G.S., additional, Sînziana, M., additional, Skovgaard, S., additional, Smith, I., additional, Sönsken, U., additional, Soriano, A., additional, Sviestiņa, I., additional, Szilagyi, E., additional, Tängdén, T., additional, Tattevin, P., additional, Tsioutis, C., additional, Vilde, A., additional, Wanke-Rytt, M., additional, Wechsler-Fördös, A., additional, and Zarb, P., additional

Published
2019
Full Text
View/download PDF

27. Acquired carbapenemases in Gram-negative bacterial pathogens: Detection and surveillance issues

Author

Miriagou, V. Cornaglia, G. Edelstein, M. Galani, I. Giske, C.G. Gniadkowski, M. Malamou-Lada, E. Martinez-Martinez, L. Navarro, F. Nordmann, P. Peixe, L. Pournaras, S. Rossolini, G.M. Tsakris, A. Vatopoulos, A. Cantón, R.

Abstract

Acquired carbapenemases are emerging resistance determinants in Gram-negative pathogens, including . Enterobacteriaceae, . Pseudomonas aeruginosa and other Gram-negative non-fermenters. A consistent number of acquired carbapenemases have been identified during the past few years, belonging to either molecular class B (metallo-β-lactamases) or molecular classes A and D (serine carbapenemases), and genes encoding these enzymes are associated with mobile genetic elements that allow their rapid dissemination in the clinical setting. Therefore, detection and surveillance of carbapenemase-producing organisms have become matters of major importance for the selection of appropriate therapeutic schemes and the implementation of infection control measures. As carbapenemase production cannot be simply inferred from the resistance profile, criteria must be established for which isolates should be suspected and screened for carbapenemase production, and for which tests (phenotypic and/or genotypic) should be adopted for confirmation of the resistance mechanism. Moreover, strategies should be devised for surveillance of carbapenemase producers in order to enable the implementation of effective surveillance programmes. The above issues are addressed in this article, as a follow-up to an expert meeting on acquired carbapenemases that was recently organized by the ESCMID Study Group for Antibiotic Resistance Surveillance. © 2010 The Authors. Journal Compilation © 2010 European Society of Clinical Microbiology and Infectious Diseases.

Published
2010

31. Meropenem-clavulanate has high in vitroactivity against multidrug-resistant Mycobacterium tuberculosis

Author

Davies Forsman, L., Giske, C.G., Bruchfeld, J., Schön, T., Juréen, P., and Ängeby, K.

Abstract

With the relentless increase in multidrug- and extensively-drug resistant tuberculosis (MDR/XDR-TB), new treatment strategies are necessary. Favorable results have been reported by combining a β-lactam antibiotic and a β-lactamase inhibitor. The β-lactamase encoded by the blaCgene of Mycobacterium tuberculosis(MTB) is the major mechanism of resistance to β-lactam antibiotics (e.g., penicillin). Meropenem, a β-lactam antibiotic of the carbapenem group, is a relatively weak substrate for the β-lactamase of MTB.The β-lactamase inhibitor clavulanate irreversibly inactivates the β-lactamase encoded by the blaCgene, thus making the combination of meropenem and clavulanate an interesting treatment alternative for MTB. However, very few isolates of MTB have been tested for this drug combination and few clinical reports exist. Thus, the present study investigates the in vitroactivity of meropenem-clavulanate for drug-resistant MTB isolates, including MDR/XDR-TB.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results